Tennessee Biotech Association – Annual Meeting

Pre-Event IP Seminar

 

TITLE:            Life Science Intellectual Property Seminar

 

DATE:            Wednesday, September 26, 2007

                        Registration and Networking: Noon – 1:00PM (CST)

                        Seminar: 1:00PM – 5:00PM (CST)

 

LOCATION:  Cool Springs Life Science Center

                        389-A Nichol Mill Lane

                        Franklin, TN  37067

                       

Phone: 615-261-2886

                        Website: www.cslsc.com

 

BRIEF DESCRIPTION OF COURSE:

 

Four hour seminar focused upon intellectual property issues – legal and economic - specific to life science companies.  Individuals from the Leudeka Neely & Graham, Fish & Richardson, Crowe Chizek and Hogan and Hartson will make presentations.  This seminar is being offered by the Tennessee Biotech Association as a pre-event seminar prior to its annual meeting which begins the next day, Thursday, September 27.

 

COURSE OUTLINE:

 

1:00 to 1:55 – Life Science Patent Prosecution

Mark Graham and Julie Birdwell - Leudeka Neely & Graham (Knoxville, TN)

This session will focus upon the unique aspects of life science patent prosecution.

 

1:55 to  2:50 – Life Science M&A Due Diligence

Tina McKeon – Fish & Richardson (Atlanta, GA)

This session will focus upon the IP due diligence issues to consider with in-licensing and acquisition transactions involving life science patents.

 

2:50 to 3:10 - Break

 

3:10 to  4:05 - Life Science IP Valuation and Damages

Glenn Perdue - Crowe Chizek (Nashville, TN)

This session will focus upon economic considerations that impact life science intellectual property in the context of asset valuation and litigation damage recoveries.

 

4:05 - 5:00 – FDA Update: Generic Biologics and Drug Reauthorization

Bob Brady – Hogan & Hartson (Washington, DC)

This session will focus upon two timely FDA topics: (i) pending legislation related to generic or Òfollow-onÓ biologics, and (ii) pending legislation involving prescription drug user fee

 reauthorization and related Phase IV (post-marketing) study commitments.

 

5:00 – 7:00 Reception